{
    "clinical_study": {
        "@rank": "152989", 
        "arm_group": {
            "arm_group_label": "Dopamine Imaging"
        }, 
        "brief_summary": {
            "textblock": "This study will examine resting dopamine function as well as dopamine response in the brain\n      as it interacts with medicines normally prescribed to subacute Traumatic Brain Injury (TBI)\n      patients."
        }, 
        "brief_title": "Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)", 
        "condition": "Traumatic Brain Injury", 
        "condition_browse": {
            "mesh_term": [
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-penetrating TBI\n\n          -  Age between 18-50 years old\n\n          -  Admitted to a North Texas TBI Model Systems-affiliated rehabilitation facility within\n             16 weeks of injury\n\n          -  Rated at Rancho VI Los Amigos Levels of Cognitive Functioning Scale of less than or\n             equal to Stage V at the time of enrollment\n\n          -  Disability Rating Scale total score >/= 7\n\n        Exclusion Criteria:\n\n          -  Central Nervous System disorder resulting in functional disability predating TBI\n\n          -  Documented diagnosis of disease processes impacted by the dopamine system (e.g.,\n             Parkinson's Disease, clinician diagnosed Attention Deficit Hyperactivity Disorder,\n             substance abuse/dependence (excluding marijuana, alcohol, tobacco), or schizophrenia)\n\n          -  Pre-injury use of dopaminergic pharmaceuticals (i.e., methylphenidate, amantadine, or\n             dopamine receptor blockers such as olanzapine or quetiapine)\n\n          -  Documented contraindication to use of methylphenidate including allergy\n\n          -  Uncontrolled epilepsy\n\n          -  Pregnant\n\n          -  Medical condition not compatible with use of Methylphenidate\n\n          -  Recent diagnosis or therapeutic study using radiopharmaceuticals\n\n          -  Contraindications to the use of Ioflupane\n\n          -  Allergic to Iodine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Traumatic Brain Injury patients in Inpatient Rehabilitation"
            }
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850290", 
            "org_study_id": "012-277", 
            "secondary_id": "H133A120098"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dopamine", 
                "Dopamine Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "TBI", 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "contact": {
                "email": "libradacallender@baylorhealth.edu", 
                "last_name": "Libby Callender", 
                "phone": "214-820-9988"
            }, 
            "contact_backup": {
                "email": "cynthidu@baylorhealth.edu", 
                "last_name": "Cindy Dunklin", 
                "phone": "214-820-9640"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75246"
                }, 
                "name": "Baylor Research Institute"
            }, 
            "investigator": {
                "last_name": "Shahid Shafi, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)", 
        "overall_contact": {
            "email": "librada.callender@baylorhealth.edu", 
            "last_name": "Libby Callender", 
            "phone": "214-820-9988"
        }, 
        "overall_contact_backup": {
            "email": "cynthidu@baylorhealth.edu", 
            "last_name": "Cindy Dunklin", 
            "phone": "214-820-9640"
        }, 
        "overall_official": [
            {
                "affiliation": "Baylor Research Institute", 
                "last_name": "Shahid Shafi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Texas Southwestern Medical Center", 
                "last_name": "Devous Michael, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure will be the change in Disability Rating Scale over 4 weeks.  The Disability Rating Scale is a commonly used and reliable instrument for monitoring minor changes occurring throughout the course of a patient's recovery (Rappaport et al., 1982).", 
            "measure": "Change in Disability Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850290"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "John F Kennedy Coma Recovery Scale Revised", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks"
            }, 
            {
                "measure": "Functional Independence Measure (FIM)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks"
            }, 
            {
                "measure": "Functional Assessment Measure (FAM)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks"
            }, 
            {
                "measure": "Orientation Log (O-Log)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks"
            }
        ], 
        "source": "Baylor Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Baylor Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}